National Bank of Canada
ITRM

National Bank of Canada’s Iterum Therapeutics ITRM Stock Holding History

National Bank of Canada’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2
Closed -$2 – 3065
2024
Q3 		$2 Hold
2
– – ﹤0.01% 2722
2024
Q2 		$2 Hold
2
– – ﹤0.01% 2683
2024
Q1 		$3 Hold
2
– – ﹤0.01% 2712
2023
Q4 		$4 Hold
2
– – ﹤0.01% 2700
2023
Q3 		$2 Hold
2
– – ﹤0.01% 2767
2023
Q2 		$2 Hold
2
– – ﹤0.01% 2718
2023
Q1 		$2 Hold
2
– – ﹤0.01% 2694
2022
Q4 		$2 Hold
2
– – ﹤0.01% 2756
2022
Q3 		$0 Hold
2
– – ﹤0.01% 2788
2022
Q2 		$0 Hold
2
– – ﹤0.01% 2884
2022
Q1 		$0 Hold
2
– – ﹤0.01% 2938
2021
Q4 		$0 Buy
+2
New +$15 ﹤0.01% 2823

Other funds holding ITRM

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
AF
Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
LF
Lee Financial Dallas, Texas $783M AUM 23.98% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

National Bank of Canada's ITRM Position: Q4 2024 in Review

National Bank of Canada sold out of Iterum Therapeutics (ITRM) in Q4 2024, closing a stake of 2 shares — an estimated $2 sold.

National Bank of Canada first reported a position in ITRM in Q4 2021 and held it in 12 quarters. The position peaked at $4 in Q4 2023. 24 funds tracked by Wall St. Rank hold ITRM as of Q4 2024.

  • National Bank of Canada reported no remaining Iterum Therapeutics position as of Q4 2024 after selling out during the quarter.
  • National Bank of Canada sold 2 Iterum Therapeutics shares in Q4 2024, an estimated $2.
  • National Bank of Canada first reported a position in Iterum Therapeutics in Q4 2021 and held it in 12 quarters.
  • National Bank of Canada's Iterum Therapeutics position peaked at $4 in Q4 2023.
  • 24 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q4 2024.

Based on National Bank of Canada's 13F filing for Q4 2024, filed 12 Feb 2025.